We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00760604
Recruitment Status : Terminated (Closed due to slow patient accrual.)
First Posted : September 26, 2008
Last Update Posted : August 13, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to test 2 different methods of surgery to remove cancer in the esophagus. This research is being done to see whether removing more tissue and lymph nodes surrounding the tumor in the esophagus (known as transthoracic en bloc esophagectomy) offers better control of the cancer than removing less tissue and lymph nodes (known as non-en bloc esophagectomy).

Condition or disease Intervention/treatment Phase
Esophageal Neoplasms Procedure: Esophagectomy Phase 3

Detailed Description:
The aim of this study is to determine the 5-year disease-free survival, overall survival, and time to progression comparing (Arm A) transthoracic en bloc esophagectomy and (Arm B) transhiatal or transthoracic non-en bloc esophagectomy. Randomization to the two surgical arms will take place after the patient has given written informed consent and eligibility has been established. Patients will be informed of their randomized arm prior to the day of surgery. Preoperative chemotherapy may be administered at the discretion of the treating physician. Adjuvant chemotherapy and/or radiotherapy will be prescribed at the discretion of the treating physician. All patients will be followed for recurrence and survival for 5 years.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Patients With Locally Advanced Esophageal Cancer
Study Start Date : September 2008
Primary Completion Date : April 2012
Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: A
En bloc esophagectomy is performed through a transthoracic approach by removing the tumor-bearing esophagus, the pericardium anteriorly, both pleural surfaces laterally, as well as the thoracic duct and all other lymphoareolar tissue wedged posteriorly between the esophagus and the spine, and en-bloc resection of all nodal groups in the middle and lower mediastinum as well as the upper abdomen.
Procedure: Esophagectomy
Comparison of en-bloc vs. non-en bloc esophagectomy
Active Comparator: B
Transhiatal esophagectomy is performed through an abdominal incision and a neck incision. The stomach is mobilized, and the left gastric vessels are transected at its origin. Celiac lymph nodes are dissected, and the intrathoracic esophagus is dissected bluntly through the hiatus and through the neck. The cervical esophagus is divided at the level of the neck. After the esophagogastrectomy is performed, a gastric tube is created. An esophagogastrostomy is then performed in the neck. If a transthoracic approach is used, dissection will be as described for the transhiatal approach.
Procedure: Esophagectomy
Comparison of en-bloc vs. non-en bloc esophagectomy

Outcome Measures

Primary Outcome Measures :
  1. Disease free survival defined as the time from surgical resection to the time of recurrent disease, death from esophageal cancer, or death from any cause. [ Time Frame: CT scans will be performed every 6 months for 5 years. ]

Secondary Outcome Measures :
  1. To determine 5-year overall and disease-specific survival in arm A and arm B [ Time Frame: CT scans every 6 months for 5 years ]
  2. To determine the rates of local and systemic recurrence in arm A vs. arm B [ Time Frame: CT scans performed every 6 months for 5 years ]
  3. To determine time to progression in arm A vs. arm B [ Time Frame: CT scans every 6 months for 5 years ]
  4. To determine mortality and morbidity in arm A vs. arm B [ Time Frame: 5 years from the date of surgical resection ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with cT2-T3/N0-N1-M1a-M1b(lymph node metastasis only) esophageal squamous cell and adenocarcinoma who have potentially resectable disease.
  • Karnofsky performance status greater than or equal to 80%.
  • Pulmonary and cardiac function must be acceptable for surgery according to institutional standards.
  • Acceptable hepatic, renal and bone marrow function.
  • Age 18 or older.
  • Patients may receive preoperative chemotherapy and/or radiation therapy as part of their clinical care.

Exclusion Criteria:

  • Patients with clearly unresectable or metastatic esophageal cancer or clinical stage I esophageal cancer.
  • Significant psychiatric illness that would interfere with patient compliance.
  • Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment.
  • Patients with a significant history of unstable cardiovascular disease (e.g., inadequately controlled hypertension, or angina; myocardial infarction within the previous 6 months; ventricular cardiac arrhythmias requiring medication; congestive heart failure that in the opinion of the treating physician should preclude the patient from protocol treatment.
  • Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or interstitial pneumonia or interstitial fibrosis.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00760604

United States, New York
Weill Medical College of Cornell Unversity
New York, New York, United States, 10065
Sponsors and Collaborators
Weill Medical College of Cornell University
Principal Investigator: Paul C Lee, M.D. Weill Medical College of Cornell University
More Information

Responsible Party: Paul C. Lee, Associate Professor of Cardiothoracic Surgery, Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT00760604     History of Changes
Other Study ID Numbers: 0806009855
First Posted: September 26, 2008    Key Record Dates
Last Update Posted: August 13, 2012
Last Verified: August 2012

Keywords provided by Paul C. Lee, Weill Medical College of Cornell University:
Esophageal neoplasms

Additional relevant MeSH terms:
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases